Cargando…
The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
Background: The management of hypertension remains suboptimal throughout the world. Methods: We performed a random-effects model meta-analysis of randomized controlled trials to determine the effectiveness and safety of sacubitril/valsartan (LCZ696) for the treatment of high arterial pressure. Relev...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268164/ https://www.ncbi.nlm.nih.gov/pubmed/34206864 http://dx.doi.org/10.3390/jcm10132824 |
_version_ | 1783720297971580928 |
---|---|
author | Chua, Su-Kiat Lai, Wei-Ting Chen, Lung-Ching Hung, Huei-Fong |
author_facet | Chua, Su-Kiat Lai, Wei-Ting Chen, Lung-Ching Hung, Huei-Fong |
author_sort | Chua, Su-Kiat |
collection | PubMed |
description | Background: The management of hypertension remains suboptimal throughout the world. Methods: We performed a random-effects model meta-analysis of randomized controlled trials to determine the effectiveness and safety of sacubitril/valsartan (LCZ696) for the treatment of high arterial pressure. Relevant published articles from PubMed, Cochrane base, and Medline were examined, and the last search date was December 2020. Only published randomized controlled trials and double-blind studies were selected for further analysis. The mean reductions in systolic blood pressure (msSBP) and diastolic blood pressure (msDBP) in the sitting position, as well as the mean reductions in ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure (maDBP), were assumed as efficacy endpoints. Adverse events (AEs) were considered as safety outcomes. Results: Ten studies with a total of 5931patients were included for analysis. Compared with placebo, LCZ696 had a significant reduction in msSBP (weight mean difference (WMD) = −6.52 mmHg, 95% confidence interval (CI): −8.57 to −4.47; p < 0.001), msDBP (WMD = −3.32 mmHg, 95% CI: −4.57 to −2.07; p < 0.001), maSBP (WMD = −7.08 mmHg, 95% CI: −10.48 to −3.68; p < 0.001), maDBP (WMD = −3.57 mmHg, 95% CI: −5.71 to −1.44, p < 0.001). In subgroup analysis, only 200 mg and 400 mg LCZ696 showed a significant BP reduction. There was no difference in the AE rate between the LCZ696 and placebo groups (WMD = 1.02, 95% CI: 0.83 to 1.27, p = 0.54). Egger’s test revealed a potential publication bias for msSBP (p = 0.025), but no publication bias for other outcomes. Conclusion: LCZ696 may reduce blood pressure more efficaciously than traditional therapy in hypertensive patients without increasing adverse effects. |
format | Online Article Text |
id | pubmed-8268164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82681642021-07-10 The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials Chua, Su-Kiat Lai, Wei-Ting Chen, Lung-Ching Hung, Huei-Fong J Clin Med Review Background: The management of hypertension remains suboptimal throughout the world. Methods: We performed a random-effects model meta-analysis of randomized controlled trials to determine the effectiveness and safety of sacubitril/valsartan (LCZ696) for the treatment of high arterial pressure. Relevant published articles from PubMed, Cochrane base, and Medline were examined, and the last search date was December 2020. Only published randomized controlled trials and double-blind studies were selected for further analysis. The mean reductions in systolic blood pressure (msSBP) and diastolic blood pressure (msDBP) in the sitting position, as well as the mean reductions in ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure (maDBP), were assumed as efficacy endpoints. Adverse events (AEs) were considered as safety outcomes. Results: Ten studies with a total of 5931patients were included for analysis. Compared with placebo, LCZ696 had a significant reduction in msSBP (weight mean difference (WMD) = −6.52 mmHg, 95% confidence interval (CI): −8.57 to −4.47; p < 0.001), msDBP (WMD = −3.32 mmHg, 95% CI: −4.57 to −2.07; p < 0.001), maSBP (WMD = −7.08 mmHg, 95% CI: −10.48 to −3.68; p < 0.001), maDBP (WMD = −3.57 mmHg, 95% CI: −5.71 to −1.44, p < 0.001). In subgroup analysis, only 200 mg and 400 mg LCZ696 showed a significant BP reduction. There was no difference in the AE rate between the LCZ696 and placebo groups (WMD = 1.02, 95% CI: 0.83 to 1.27, p = 0.54). Egger’s test revealed a potential publication bias for msSBP (p = 0.025), but no publication bias for other outcomes. Conclusion: LCZ696 may reduce blood pressure more efficaciously than traditional therapy in hypertensive patients without increasing adverse effects. MDPI 2021-06-26 /pmc/articles/PMC8268164/ /pubmed/34206864 http://dx.doi.org/10.3390/jcm10132824 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chua, Su-Kiat Lai, Wei-Ting Chen, Lung-Ching Hung, Huei-Fong The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title | The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_full | The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_fullStr | The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_short | The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_sort | antihypertensive effects and safety of lcz696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268164/ https://www.ncbi.nlm.nih.gov/pubmed/34206864 http://dx.doi.org/10.3390/jcm10132824 |
work_keys_str_mv | AT chuasukiat theantihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT laiweiting theantihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT chenlungching theantihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT hunghueifong theantihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT chuasukiat antihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT laiweiting antihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT chenlungching antihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT hunghueifong antihypertensiveeffectsandsafetyoflcz696inpatientswithhypertensionasystemicreviewandmetaanalysisofrandomizedcontrolledtrials |